Marinus Pharmaceuticals
MRNS
ATLANTA, GA – – (Globe Newswire – June 6, 2024) – – A shareholder class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. (“Marinus” or the “Company”) (NASDAQ: MRNS). The lawsuit alleges that Defendants made materially false and misleading statements and/or failed to disclose material adverse information regarding the Company’s business, operations, and prospects, including allegations that: (1) Defendants understated the risk of failure to meet the early-stopping criteria in the RAISE trial; and (2) Defendants did not disclose that a possible consequence of failing to meet the early stopping criteria in the RAISE trial would be that Marinus would stop the separate Phase 3 RAISE II trial.
If you bought Marinus shares between March 17, 2021 and May 7, 2024, and suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888)-508-6832 or, you may visit the firm’s website at www.holzerlaw.com/case/marinus-pharmaceuticals/ to learn more.
The deadline to ask the court to be appointed lead plaintiff in the case is August 5, 2024.
Registration Deadline
Lead Plaintiff Deadline Has Passed
August 5, 2024